Clinical Trial

Pembrolizumab for Newly Diagnosed Glioblastoma

Study acronym: PERGOLA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-04-01; most recent amendment 2024-05-07.
Status change: Recruiting → Active, Not Recruiting 2022-02-21
Status change: Not Yet Recruiting → Recruiting 2020-11-03
Trial Details
NCT Number NCT03899857
Lead Sponsor University of Zurich
Collaborators: Merck Sharp & Dohme LLC
Conditions Newly Diagnosed Glioblastoma
Enrollment 56 participants
Start Date 2020-10-21
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-05-08